Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 15/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27603568 | 1.00 | CTSA (0.51) | CTSAPOLBCACNA1B | |
| SCHEMBL3447780 | 0.90 | CACNA1B (0.47) | CTSAPOLBCACNA1B | |
| SCHEMBL14044920 | 0.86 | CTSS (0.45) | POLBCACNA1B | |
| SCHEMBL1738732 | 0.86 | CTSS (0.45) | POLBCACNA1B | |
| SCHEMBL29582289 | 0.86 | CTSS (0.45) | POLBCACNA1B | |
| SCHEMBL19744367 | 0.85 | CTSA (0.55) | CTSA | |
| SCHEMBL22805380 | 0.85 | CTSS (0.44) | CACNA1B | |
| SCHEMBL31757886 | 0.85 | CTSS (0.44) | CTSA | |
| SCHEMBL19744371 | 0.85 | CTSA (0.55) | CTSA | |
| SCHEMBL31757758 | 0.85 | CTSA (0.55) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262005-A1 | Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262005-A1 | Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2005113516-A1 | URACIL-TYPE GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262005-A1 | Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto | GNRHR, FSHR, GHRHR | CTSA 1670/4885POLB 635/4885CACNA1B 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.